Immunogenicity of Pseudomonas Aeruginosa Recombinant B-Type Fagellin As a Vaccine Candidate: Protective Efficacy in a Murine Burn Wound Sepsis Model Publisher



Behrouz B^{1, 2, 3, 4} ; Mahdavi M^{1, 2, 3, 4} ; Amirmozafari N^{1, 2, 3, 4} ; Fatemi MJ^{1, 2, 3, 4} ; Irajian G^{1, 2, 3, 4} ; Bahroudi M^{1, 2, 3, 4} ; Hashemi FB^{1, 2, 3, 4} Show Affiliations
Source: Burns Published:2016

Abstract

Pseudomonas aeruginosa (PA) is a formidable opportunistic pathogen among patients with burn wound infections. Antimicrobial therapy is often unsuccessful because PA can develop multi-drug resistance; thus, immunotherapy can be a rational alternative. The goal of this study was to evaluate the immunogenicity recombinant type b flagellin (r-b-flagellin) as a potential vaccine against P. aeruginosa in a mouse model for burn wound sepsis. Primary immunization with r-b-flagellin (10. μg) followed by two booster shots was sufficient to generate a robust humoral response, which was predominantly a T helper 2 (Th2) type response consisting mainly of subtype IgG1 and low levels of IgG2a. Analysis of the Th1-Th2 response among immunized mice showed an increased production of IL-4, INF-γ and IL-17 by splenocytes upon stimulation by r-b-flagellin. Opsono-phagocytosis assays confirmed the enhanced killing of bacteria by anti r-b-flagellin immune sera. These antibodies were also able to inhibit motility of P. aeruginosa and afforded protection to immunized mice by reducing bacterial load in the site of original infection into the liver of challenged mice. The reduction of systemic bacterial spread resulted in an increase in the survival rate of challenged immunized mice. In conclusion, immunization of mice with r-b-flagellin protein increased the level of humoral and cellular immune response and led to an efficacious protection against P. aeruginosa infection in the burn mouse model. © 2016 Elsevier Ltd and ISBI.